INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 201 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 1.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,650,621 | +1.7% | 601,322 | +13.7% | 1.30% | +1.6% |
| Q4 2022 | $6,541,875 | +346.5% | 528,850 | +403.7% | 1.28% | +263.2% |
| Q3 2022 | $1,465,000 | -96.7% | 105,000 | -73.8% | 0.35% | -92.0% |
| Q1 2019 | $44,744,000 | +122.0% | 400,000 | +100.0% | 4.43% | +73.8% |
| Q4 2018 | $20,158,000 | +56.9% | 200,000 | +100.0% | 2.55% | -44.7% |
| Q1 2016 | $12,847,000 | – | 100,000 | – | 4.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |